Does testosterone mediate the relationship between vitamin D and prostate cancer progression? A systematic review and meta-analysis.


Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 23 06 2021
accepted: 20 05 2022
pubmed: 27 6 2022
medline: 14 7 2022
entrez: 26 6 2022
Statut: ppublish

Résumé

Observational studies and randomized controlled trials (RCTs) have shown an association between vitamin D levels and prostate cancer progression. However, evidence of direct causality is sparse and studies have not examined biological mechanisms, which can provide information on plausibility and strengthen the evidence for causality. We used the World Cancer Research Fund International/University of Bristol two-stage framework for mechanistic systematic reviews. In stage one, both text mining of published literature and expert opinion identified testosterone as a plausible biological mechanism. In stage two, we performed a systematic review and meta-analysis to assess the evidence from both human and animal studies examining the effect of vitamin D on testosterone, and testosterone on advanced prostate cancer (diagnostic Gleason score of ≥ 8, development of metastasis) or prostate cancer-specific mortality. A meta-analysis of ten human RCTs showed evidence of an effect of vitamin D on total testosterone (standardised mean difference (SMD) = 0.133, 95% CI =  - 0.003-0.269, I There is some evidence that vitamin D increases levels of total and free testosterone, although the effect of testosterone levels within the normal range on prostate cancer progression is unclear. The role of testosterone as a mechanism between vitamin D and prostate cancer progression remains inconclusive.

Identifiants

pubmed: 35752985
doi: 10.1007/s10552-022-01591-w
pii: 10.1007/s10552-022-01591-w
pmc: PMC9270305
doi:

Substances chimiques

Vitamins 0
Vitamin D 1406-16-2
Testosterone 3XMK78S47O

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1025-1038

Subventions

Organisme : world cancer research fund international
ID : WCRF 2015/1421

Informations de copyright

© 2022. The Author(s).

Références

Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Horm Metab Res. 2011 Mar;43(3):223-5
pubmed: 21154195
Eur Urol. 2008 Jan;53(1):106-11
pubmed: 17482753
J Clin Endocrinol Metab. 2012 Jul;97(7):2315-24
pubmed: 22508710
Endocr Connect. 2018 Dec 1;7(12):R294-R303
pubmed: 30352424
Eur J Nutr. 2019 Mar;58(2):673-680
pubmed: 29546692
Clin Genitourin Cancer. 2018 Jun;16(3):165-175.e2
pubmed: 29454638
BMC Med Res Methodol. 2014 Feb 21;14:30
pubmed: 24559167
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3148-3156
pubmed: 30896763
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
N Engl J Med. 2009 Mar 26;360(13):1320-8
pubmed: 19297566
Eur J Nutr. 2019 Dec;58(8):3135-3146
pubmed: 30460609
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Target Oncol. 2017 Oct;12(5):695-701
pubmed: 28712059
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
J Clin Endocrinol Metab. 2013 Apr;98(4):1498-507
pubmed: 23463655
BJU Int. 2010 Mar;105(6):824-9
pubmed: 19751256
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2874-81
pubmed: 19861519
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
Endocrine. 2021 Apr;72(1):49-61
pubmed: 32880851
Nutrients. 2018 Dec 12;10(12):
pubmed: 30545134
Nutrients. 2020 May 04;12(5):
pubmed: 32375348
Eur Urol. 2014 Apr;65(4):683-9
pubmed: 23340241
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1314-22
pubmed: 20378270
Horm Metab Res. 2013 Sep;45(9):675-81
pubmed: 23686706
J Clin Endocrinol Metab. 2017 Nov 1;102(11):4292-4302
pubmed: 28938446
Clin Endocrinol (Oxf). 2015 Jul;83(1):105-10
pubmed: 25557316
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1667-1675
pubmed: 28978562
Syst Rev. 2019 Feb 12;8(1):52
pubmed: 30755270
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Andrologia. 2019 Oct;51(9):e13343
pubmed: 31332821
Cancer Causes Control. 2017 Jun;28(6):497-528
pubmed: 28361446
Open Access J Sports Med. 2015 Jul 24;6:229-39
pubmed: 26244032
Int J Sport Nutr Exerc Metab. 2020 Feb 4;30(2):165–173
pubmed: 32023539
BMJ. 2018 Sep 05;362:k3519
pubmed: 30185521
Cancer. 2017 Jun 15;123(12):2312-2319
pubmed: 28436011
JAMA. 2019 Apr 9;321(14):1370-1379
pubmed: 30964527
JAMA. 2019 Apr 9;321(14):1361-1369
pubmed: 30964526
Clin Endocrinol (Oxf). 2018 Feb;88(2):217-226
pubmed: 29095521

Auteurs

Luke A Robles (LA)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England. luke.robles@bristol.ac.uk.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England. luke.robles@bristol.ac.uk.
NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, England. luke.robles@bristol.ac.uk.

Sean Harrison (S)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.

Vanessa Y Tan (VY)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.

Rhona Beynon (R)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.

Alexandra McAleenan (A)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.

Julian Pt Higgins (JP)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.
NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, England.

Richard M Martin (RM)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.
NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, England.

Sarah J Lewis (SJ)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.
NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, England.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH